Predictors of death in COVID-19 vaccine breakthrough infections in Brazil

Risk and outcomes of breakthrough COVID‐19 infections in vaccinated immunocompromised patients: A meta‐analysis

“…Guangtong Deng 1,2,# Qian Zhou 1,2,# Yu Meng 1,2 Huiyan Sun 1,2 Songtao Du 3 Yihuang Liu 1,2 Furong Zeng 4, *…”

“…

Dear Editor, Breakthrough infection, which is defined as reinfection of coronavirus disease 2019 (COVID-19) after vaccination with a typical 14-day lag period, has been recorded. 1 However, concerns have been raised regarding the potential risk and outcomes of breakthrough COVID-19 infections between immunocompromised and immunocompetent patients. 2,3 To fill in the gaps, we performed the meta-analysis with two key questions explored: are immunocompromised patients related to an increased risk of breakthrough COVID-19 infections, hospitalization, and mortality; and are different subtypes of immunocompromised patients associated with different risk and outcomes of breakthrough COVID-19 infections?This meta-analysis was based on the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines.

…”

Epidemiological and clinical characteristics of vaccinated COVID-19 patients: A meta-analysis and systematic review

“…A total of 14 studies were included to analyze the effect of age. We found no statistical difference in the age of the two groups (SMD = 0.085, 95% CI = À0.073-0.189, p = 0.388, 12 Case-control study 346 1100 ☆☆☆ ☆☆ ☆☆ 7☆ Wi 18 Case-control study 142 20 ☆☆ ☆☆ ☆☆ 6☆ Tenforde 13 Case-control study 314 1669 ☆☆☆ ☆☆ ☆☆ 7☆ Hsu 19 Case-control study 85 85 ☆☆ ☆☆ ☆☆☆ 7☆ Blanquart 20 Case-control study 724 5459 ☆☆☆ ☆☆ ☆☆ 7☆ Bollineni 21 Case-control study 14 56 ☆ ☆☆ ☆☆☆ 6☆ Marincu 22 Case-control study 62 62 ☆☆ ☆☆ ☆☆☆ 7☆ Wolff 23 Case-control study 260 507 ☆☆☆ ☆☆ ☆☆☆ 8☆ Kalligeros 24 Case-control study 91 824 ☆☆☆ ☆☆ ☆☆☆ 8☆ Fragoulis 25 Cohort study 101 60 ☆☆☆ ☆☆ ☆☆☆ 8☆ Trunfio 26 Cohort study 55 110 ☆☆☆ ☆☆ ☆☆ 7☆ Safdar 27 Cohort study 45 65 ☆☆☆ ☆☆ ☆☆☆ 8☆ Bouton 28 Cohort study 96 329 ☆☆ ☆☆ ☆☆☆ 7☆ Bosch 29 Case-control study 126 839 ☆☆ ☆☆ ☆☆☆ 7☆ Christensen 30 Case-control study 3346 13,619 ☆☆☆ ☆☆ ☆☆☆ 8☆ Yu 31 Case-control study 23 50 ☆☆☆ ☆☆ ☆☆☆ 8☆ Bayhan 32 Case-control study 38 190 ☆☆☆ ☆☆ ☆☆☆ 8☆ Kustin 33 Case-control study 396 396 ☆☆ ☆☆ ☆☆ 6☆ Toda 34 Case-control study 11 15 ☆☆☆ ☆☆ ☆☆☆ 8☆ Tian 4 Case-control study 88 41 ☆☆☆ ☆☆ ☆☆☆ 8☆ Sayed 35 Case-control study 50 70 ☆☆☆ ☆☆ ☆☆☆ 8☆ Lee 36 Case-control study 174 587 ☆☆☆ ☆☆ ☆☆☆ 8☆ Luo 37 Case-control study 484 1782 ☆☆☆ ☆☆ ☆☆ 7☆ Puhach 38 Case-control study 139 245 ☆☆ ☆☆ ☆☆ 6☆ Whittaker 39 Case-control study 716 2487 ☆☆☆ ☆☆ ☆☆☆ 8☆ Sanghavi 40 Case-control study 149 478 ☆☆☆ ☆☆ ☆☆☆ 8☆ Butt (1) 41 Case-control study 250 250 ☆☆☆ ☆☆ ☆☆☆ 8☆ Butt (2) 42 Case-control study 456 456 ☆☆☆ ☆☆ ☆☆☆ 8☆ Spiera 43 Case-control study 88 2317 ☆☆ ☆☆ ☆☆☆ 7☆ Baltas 44 Case-control study 119 476 ☆☆☆ ☆☆ ☆☆ 7☆ John 45 Case-control study 254 508 ☆☆ ☆☆ ☆☆ 6☆ Jacobson 46 Case-control study 189 471 ☆☆ ☆☆ ☆☆ 6☆ Estofolete …”

Hidroxicloroquina para Pacientes com COVID-19 não Hospitalizados: Uma Revisão Sistemática e Metanálise de Ensaios Clínicos Randomizados

“…Ainda, os estudos incluídos na metanálise são anteriores à vacinação, quando se esperava um grupo controle com uma média de 7% de internação. Ao se considerar taxas de internação por COVID-19 muito menores para o grupo controle na fase atual da pandemia, 38 o OIS seria bem maior que o estimado. Assim, a necessidade de amostras maiores, combinada com prioridades de pesquisa na fase pós-vacina, dificulta a realização de estudos maiores.…”